Full-year 2025 guidance: non-GAAP operating margin -- Expected between 23.5% and 24.5%, reflecting increases in sales and ...

Net Income -- $7.6 million, down from $9.3 million. Net income attributable to Karat ( KRT +1.51%) was $7.3 million, or $0.36 ...

Q4 2025 guidance -- Projected total revenue of $371 million to $377 million; subscription revenue of $258 million to $261 ...

Relacorilant NDA updates -- FDA PDUFA date set for Dec. 30, 2025 (hypercortisolism); platinum-resistant ovarian cancer PDUFA ...

Acquisition Announcement -- VSE Corporation ( VSEC 0.75%) signed a definitive agreement to acquire Aero 3 for $350 million in ...

Upcoming product launches -- AMP-007 inhalation on track for mid-2026 launch targeting a $1.5 billion market; generic ...

PN-943 (IBD Program) -- Oral, gut-restricted alpha-4-beta-7 integrin antagonist demonstrated greater than threefold improved ...

BradyScan App Launch -- Announced as available on Android and Apple, supporting barcode generation, scanning, security ...

gTLD process -- The ICANN 2026 round of new generic Top-Level Domains is intended to start in Q2 2026, with no future ...

Join us as we dissect Lululemon's stock performance and explore whether it can reclaim its former glory in the competitive ...

Earlier this year, Bill Ackman's fund took a large stake in a company that it views as a free cash flow machine with ...

One clinical-stage biotech is defying gravity—here’s why its record-breaking run is catching institutional attention.